Weekly Analysts’ Ratings Updates for Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals (NASDAQ: MIRM) recently received a number of ratings updates from brokerages and research firms:

• 5/9/2026 – Mirum Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/7/2026 – Mirum Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 5/7/2026 – Mirum Pharmaceuticals had its price target raised by Royal Bank Of Canada from $128.00 to $142.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Mirum Pharmaceuticals had its price target raised by TD Cowen from $125.00 to $145.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Mirum Pharmaceuticals had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $165.00 price target on the stock.
• 5/7/2026 – Mirum Pharmaceuticals was given a new $185.00 price target by HC Wainwright.
• 5/7/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Evercore Inc. They now have a $138.00 price target on the stock.
• 5/7/2026 – Mirum Pharmaceuticals was given a new $136.00 price target by Stifel Nicolaus.
• 5/7/2026 – Mirum Pharmaceuticals was upgraded by Royal Bank Of Canada to “moderate buy”.
• 5/7/2026 – Mirum Pharmaceuticals had its price target raised by Robert W. Baird from $112.00 to $129.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Mirum Pharmaceuticals had its price target raised by Morgan Stanley from $130.00 to $140.00. They now have an “overweight” rating on the stock.
• 5/4/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $150.00 to $175.00. They now have a “buy” rating on the stock.
• 4/29/2026 – Mirum Pharmaceuticals had its price target raised by Stifel Nicolaus from $125.00 to $130.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Mirum Pharmaceuticals had its price target raised by Robert W. Baird from $95.00 to $112.00. They now have an “outperform” rating on the stock.
• 4/27/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $130.00 to $150.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Mirum Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/21/2026 – Mirum Pharmaceuticals had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $132.00 price target on the stock.
• 3/27/2026 – Mirum Pharmaceuticals had its price target raised by TD Cowen from $117.00 to $125.00. They now have a “buy” rating on the stock.
• 3/23/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.

Insider Activity

In other news, SVP Jolanda Howe sold 4,732 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $435,249.36. Following the transaction, the senior vice president owned 8,429 shares in the company, valued at $775,299.42. This trade represents a 35.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued at $17,872,541.82. This trade represents a 17.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 76,806 shares of company stock worth $7,064,616. Insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.